Phytopharm Plc

Other

Glaxo Wellcome Inc.

University College Cardiff Consultants Limited

The Wellcome Foundation Limited

Paul Barraclough

Daryl David Rees

Alan T Hudson

Yaer Hu

Zongqin Xia

Sadie Vile

Phil Gunning

Jim Hanson

Clifford J Harris

Ann Louise Walker

George Stuart Cockerill

Stephen Barry Guntrip

Kathryn Jane Smith

David Drysdale Miller

Karl Witold Franzmann

Patrick Vivian Shannon

Laddawan Chunchatprasert

Martin John Page

Noelle Callizot

Patrick A Howson

Antonia Orsi

Stephen Carl McKeown

Phillip James Gunning

Pierre P Debont

Daryl Rees

Chemical compounds

The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical compositions are also disclosed.

5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical compositions are also disclosed

5-&#x3b2;-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

Substituted heteroaromatic compounds of formula (A) wherein X is N or CH; in which (a) represents a fused 5, 6 or 7-membered heterocyclic ring and R,is a group ZR,wherein Z is joined to R,through a (CH,)p group in which p is 0, 1, or 2 and Z represents a group V(CH,), V(CF,), (CH,)V, (CF,)V, V(CRR&prime;), V(CHR) or V where R and R&prime; are each C,alkyl and in which V is a hydrocarbyl group containing 0, 1 or 2 carbon atoms, carbonyl, dicarbonyl, CH(OH), CH(CN), sulphonamide, amide, O, S(O),or NR,where R,is hydrogen or R,is C,alkyl; and R,is an optionally substituted C,cycloalkyl or an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety; or R,is a group ZR,in which Z is NR,, and NR,and R,together form an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety, are protein tyrosine kinase inhibitors. The compounds are described, as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of psoriasis, fibrosis, atherosclerosis, restenosis, auto-immune disease, allergy, asthma, transplantation rejection, inflammation, thrombosis, nervous system diseases, and cancer.

Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Heterocyclic compounds

Compounds of the general formula ##STR1## wherein the various substituents are defined hereinbelow. These compounds have anti-aggregatory effect on blood platelets and are useful in the treatment or prophylaxis of thrombo-embolic disorders. Processes for the preparation of the compounds are described.

2,4-Diazabicyclo[3.3.0]octane-3,7-diones

Compounds of the general formula ##STR1## [wherein X represents a sulphur atom (--S--) or oxygen atom (--O--) in the .alpha. or .beta.-configuration;

Anti-thrombotic diazabicyclooctanediones

Growing community of inventors

Maidstone, United Kingdom

Paul Barraclough